Navigation Links
Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy
Date:12/29/2010

SEATTLE, Dec. 29, 2010 /PRNewswire-FirstCall/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced results from the Phase 1/2 clinical trial of OMS201, the Company's urological PharmacoSurgery™ product candidate. OMS201 is a proprietary combination of an anti-inflammatory agent and a smooth muscle relaxant, each with well-known safety and pharmacologic profiles.

Based on the successfully completed Phase 1 trial of a lower concentration of OMS201, this Phase 1/2 study was designed to evaluate the safety and systemic absorption of two sequentially higher concentrations of OMS201 added to standard irrigation solution and delivered to patients undergoing ureteroscopy for removal of ureteral or renal stones. This multicenter, double-blind, placebo-controlled study also explored potential efficacy endpoints but was not powered to assess efficacy. Based on an interim analysis of the pharmacokinetic data, which demonstrated low maximal systemic absorption of the active ingredients, trial enrollment was truncated from the originally planned 36 patients to a total of 24 patients.

OMS201 was safe and well tolerated in this study. The incidence of adverse events was similar in the two OMS201-concentration arms and the group receiving vehicle. No adverse events were considered treatment-related by investigators. There were no deaths or discontinuations for adverse events. Only one serious adverse event was reported, which occurred in a vehicle-treated patient.

"We are pleased with the results of this trial, which demonstrated an absence of side-effects even at a concentration of OMS201 ten times higher than that examined in our earlier Phase 1 clinical study," said Gregory A. Demopulos, M.D., chairman and
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update
2. Omeros to Present at the BioCentury NewsMakers Conference
3. Omeros Enrolls First Patient in Phase 2b Clinical Trial Evaluating OMS302 in Patients Undergoing Cataract Surgery
4. Omeros Successfully Unlocks Orphan GPCRs
5. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
6. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
8. Daniel K. Spiegelman Elected to Board of Directors of Omeros
9. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
10. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
11. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... NEW YORK , Aug. 20, 2014 /PRNewswire/ ... report is available in its catalogue: ... U.S. IVD Industry http://www.reportlinker.com/p01618927/The-Impact-of-Healthcare-Reform-PPACA-On-the-US-IVD-Industry.html ... Care Act" (H.R. 3590) is complex legislation that ... many of its provisions are beginning to take ...
(Date:8/20/2014)... , Aug. 20, 2014 Reportbuyer.com has added ... Defibrillators Industry https://www.reportbuyer.com/product/98394/Global-Cardiac-Defibrillators-Industry.html ... in US$ Million by the following Product Segments: Implantable/Internal ... comprehensive analytics for the US, Canada ... , Asia-Pacific , ...
(Date:8/20/2014)... , August 20, 2014 ... market report titled "Monochloroacetic Acid (MCA) Market for Cellulosics, ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... valued at USD 817.1 million in 2013 and is ... at a CAGR of 3.6% during the forecast period ...
Breaking Medicine Technology:The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 3The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 4The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 5The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 6Global Cardiac Defibrillators Industry 2Global Cardiac Defibrillators Industry 3Global Cardiac Defibrillators Industry 4Global Cardiac Defibrillators Industry 5Global Cardiac Defibrillators Industry 6Global Cardiac Defibrillators Industry 7Global Cardiac Defibrillators Industry 8Global Cardiac Defibrillators Industry 9Global Cardiac Defibrillators Industry 10Global Cardiac Defibrillators Industry 11Global Cardiac Defibrillators Industry 12Global Cardiac Defibrillators Industry 13Global Cardiac Defibrillators Industry 14Global Cardiac Defibrillators Industry 15Global Cardiac Defibrillators Industry 16Global Cardiac Defibrillators Industry 17Global Cardiac Defibrillators Industry 18Global Cardiac Defibrillators Industry 19Global Cardiac Defibrillators Industry 20Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 2Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 3Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 4
... July 30 Peptimmune, Inc. a privately,held ... US Patent Number,7,381,790 (the ,790 patent) which ... peptide copolymer for the treatment of autoimmune ... Phase Ib multiple-ascending dose,double-blind, placebo-controlled randomized study ...
... issues a review of,Generex Biotechnology Corporation (Nasdaq: ... Platform, Sets the Tone as Best in,Class Followed ... This review is available at website: http://www.scimitarequity.com ... development, and commercialization,of drug delivery systems and technologies. ...
Cached Medicine Technology:Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis 2Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis 3Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC 2
(Date:8/20/2014)... Loss of brain cells that act as a "sleep ... falling and staying asleep, a new study suggests. ... and often results in nighttime confusion and wandering, according ... the Rush Memory and Aging Project, which includes nearly ... being followed until death, at which point their brains ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, 2014 ... been an option, but a new study shows that only ... common reasons women didn,t undergo reconstruction was that they felt ... they were focused on their cancer treatment," said lead researcher ... Kettering Cancer Center, in New York City. Also common ...
(Date:8/20/2014)... one of the most persistent and deadliest infectious diseases ... each year. , Scientists who study tuberculosis have long ... spread from humans in Africa to seals and sea ... transmitted it to Native people there before Europeans landed ... Reveal Seals as a Source of New World Human ...
(Date:8/20/2014)... Salt Lake City, Utah (PRWEB) August 20, 2014 ... the Inc. 500’s 2014 list of the nation’s fastest growing ... overall growth in the health care sector. Connexion Point is ... specializes in contact centers in Medicare and Medicaid, and its ... in the nation. Connexion Point employs 1,000 people and has ...
(Date:8/20/2014)... YORK, NY (August 20, 2014) Research from Columbia ... critical role in stomach cancer growth and that blocking ... an effective treatment for the disease. The study was ... in collaboration with Duan Chen, MD, PhD, in Norway ... Translational Medicine . , "Scientists have long observed that ...
Breaking Medicine News(10 mins):Health News:Seniors' Sleep Woes May Be Linked to Loss of Brain Cells 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3Health News:With 3943.8% Growth, Connexion Point, a Leader in Contact Centers for Health Care, Ranks 86th on the Inc. 500 List as One of the Nation’s Fastest Growing Companies 2Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2
... in minimally invasive surgical techniques -- most notably, ... common surgical option across the United States for ... , A newer, third option is a hybrid ... safe and effective and compares favorably with standard ...
... Software Complies with 100% of Updated Interoperability RequirementsTAMPA, ... a leading provider of electronic health records, today ... Technology (CCHIT(R)) has approved Sage,s product, Sage Intergy ... Ambulatory EHR , additionally certified ...
... Managing Turnover According to Cejka Search and AMGA ... to the current economic crisis is that physicians ... However, with the physician shortage intensifying and ... sharpening their competitive edge in finding and keeping ...
... surgical approach to treat stomach cancer has been shown ... treatment for some patients. , A new study led ... traditional "open" surgery to remove the stomach with laparoscopic ... surgeon removes the stomach while guided by a magnified ...
... thyroid cancer is being held today at the United Nations ... of thyroid cancer among millions of people around the world ... in Ukraine on April 26, 1986. ... (NYEEI) is working in partnership with Project Chernobyl, a ...
... Therapeutics, Inc. announced today positive results from a ... evaluating fenretinide for the treatment of geographic atrophy ... analysis was triggered when all patients had reached ... http://www.newscom.com/cgi-bin/prnh/20080220/CLW064LOGO )The analysis compared the ...
Cached Medicine News:Health News:Helping hand of hybrid surgery benefits colorectal patients 2Health News:Sage Intergy EHR Receives 08 CCHIT Certification 2Health News:Sage Intergy EHR Receives 08 CCHIT Certification 3Health News:Sage Intergy EHR Receives 08 CCHIT Certification 4Health News:Sage Intergy EHR Receives 08 CCHIT Certification 5Health News:The Economy Plus Flexibility Keep Physicians in Practice 2Health News:The Economy Plus Flexibility Keep Physicians in Practice 3Health News:The Economy Plus Flexibility Keep Physicians in Practice 4Health News:New minimally invasive surgery option for patients with stomach cancer 2Health News:'Living With Radiation' Conference Commemorating Chernobyl Nuclear Disaster Held at United Nations, Sponsored by New York Eye & Ear Infirmary 2Health News:Sirion Therapeutics Announces Positive Results From Interim Analysis of Phase II Trial and Receives FDA Fast Track Designation for Fenretinide 2Health News:Sirion Therapeutics Announces Positive Results From Interim Analysis of Phase II Trial and Receives FDA Fast Track Designation for Fenretinide 3
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
Medicine Products: